

ROCKWELL MEDICAL TECHNOLOGIES INC
Form 10QSB
November 14, 2005

=====
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-QSB

(Mark One)

[x] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the quarterly period ended September 30, 2005

[] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the transition period from _____ to _____

Commission File Number: 000-23-661

ROCKWELL MEDICAL TECHNOLOGIES, INC.
(Exact name of small business issuer as specified in its charter)

Michigan

38-3317208

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

30142 Wixom Road
Wixom, Michigan 48393

(Address of principal executive offices)

(248) 960-9009

(Issuer's telephone number)

(Former name, former address and former fiscal year, if changed since last report)

Check whether the issuer: (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes [X] No []

Indicate by check mark whether the issuer is a shell company (as defined by Rule 12b-2 of the Exchange Act. Yes [] No [X]

State the number of shares outstanding of each of the issuer's classes of common equity as of the latest practicable date: 8,790,067 Common Shares outstanding as of November 8, 2005.

Edgar Filing: ROCKWELL MEDICAL TECHNOLOGIES INC - Form 10QSB

Transitional Small Business Disclosure Format (Check one):

Yes [] No [X]

=====

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS.

ROCKWELL MEDICAL TECHNOLOGIES, INC. AND SUBSIDIARY

CONSOLIDATED BALANCE SHEETS

As of September 30, 2005 and December 31, 2004

(Whole Dollars)

(Unaudited)

	September 30, 2005	De
	-----	---
ASSETS		
Cash and Cash Equivalents	\$ 451,325	\$
Restricted Cash Equivalents	8,662	
Accounts Receivable, net of a reserve of \$53,000 in 2005 and \$44,500 in 2004	2,702,181	
Inventory	2,062,523	
Other Current Assets	669,020	
	-----	---
Total Current Assets	5,893,711	
Property and Equipment, net	2,068,157	
Intangible Assets	400,499	
Goodwill	920,745	
Other Non-current Assets	128,742	
	-----	---
TOTAL ASSETS	\$ 9,411,854	\$
	=====	==
LIABILITIES AND SHAREHOLDERS' EQUITY		
Short Term Borrowings	\$ 1,400,000	\$
Notes Payable & Capitalized Lease Obligations	449,608	
Accounts Payable	1,503,104	
Customer Deposits	1,078,345	
Accrued Liabilities	400,414	
	-----	---
Total Current Liabilities	4,831,471	
Long Term Notes Payable & Capitalized Lease Obligations	566,051	
Shareholders' Equity:		
Common Share, no par value, 8,697,384 and 8,556,531 shares issued and outstanding	12,146,094	
Common Share Purchase Warrants, 3,700,000 and 3,761,071 shares issued and outstanding	286,130	
Accumulated Deficit	(8,417,892)	

Edgar Filing: ROCKWELL MEDICAL TECHNOLOGIES INC - Form 10QSB

Total Shareholders' Equity	4,014,332	
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	\$ 9,411,854	\$

The accompanying notes are an integral part of the consolidated financial statements.

2

ROCKWELL MEDICAL TECHNOLOGIES, INC. AND SUBSIDIARY

CONSOLIDATED INCOME STATEMENTS

For the three and nine months ended September 30, 2005 and September 30, 2004

(WHOLE DOLLARS)

(Unaudited)

	Three Months Ended Sept. 30, 2005	Three Months Ended Sept. 30, 2004	Nine Months Ended Sept. 30, 2005	Nine Mo Ende Sept. 30
SALES	\$ 7,828,262	\$ 4,473,872	\$21,238,803	\$13,164
Cost of Sales	6,868,274	3,753,177	18,798,954	11,066
GROSS PROFIT	959,988	720,695	2,439,849	2,097
Selling, General and Administrative	758,819	606,304	2,094,945	1,759
OPERATING INCOME	201,169	114,391	344,904	338
Other Income	--	--	137,468	
Interest Expense, net	44,992	49,114	131,524	138
Net Income	\$ 156,177	\$ 65,277	\$ 350,848	\$ 200
BASIC EARNINGS PER SHARE	\$.02	\$.01	\$.04	\$
DILUTED EARNINGS PER SHARE	\$.02	\$.01	\$.04	\$

The accompanying notes are an integral part of the consolidated financial statements.

3

ROCKWELL MEDICAL TECHNOLOGIES, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF CASH FLOWS

For the nine months ended September 30, 2005 and September 30, 2004

Edgar Filing: ROCKWELL MEDICAL TECHNOLOGIES INC - Form 10QSB

(WHOLE DOLLARS)
(Unaudited)

	2005	2004
	-----	-----
CASH FLOWS FROM OPERATING ACTIVITIES:		
NET INCOME	\$ 350,848	\$ 200,118
Adjustments To Reconcile Net Income To Net Cash Used For Operating Activities:		
Depreciation and Amortization	516,217	462,250
Changes in Assets and Liabilities:		
(Increase) in Accounts Receivable	(400,088)	(133,302)
(Increase) in Inventory	(410,066)	(87,421)
(Increase) in Other Assets	(565,535)	(37,795)
(Decrease) Increase in Accounts Payable	(621,575)	268,769
Increase in Customer Deposits	1,067,340	--
(Decrease) Increase in Other Liabilities	(81,173)	116,898
	-----	-----
Changes in Assets and Liabilities	(1,011,097)	127,149
	-----	-----
CASH PROVIDED BY OPERATING ACTIVITIES	(144,032)	789,517
CASH FLOWS FROM INVESTING ACTIVITIES:		
Purchase of Equipment	(445,813)	(277,149)
Purchase of Intangible Assets	(56,478)	(75,000)
	-----	-----
CASH (USED IN) INVESTING ACTIVITIES	(502,291)	(352,149)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Proceeds from Borrowing on Line of Credit	5,537,395	12,147,230
Payments on Line of Credit	(4,590,077)	(12,415,374)
Payments on Notes Payable and Capital Lease Obligations	(257,030)	(246,713)
Issuance of Common Shares	241,165	32,876
	-----	-----
CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES ..	931,453	(481,981)
INCREASE IN CASH	285,130	(44,613)
CASH AT BEGINNING OF PERIOD	166,195	106,639
	-----	-----
CASH AT END OF PERIOD	\$ 451,325	\$ 62,026
	=====	=====
Supplemental Cash Flow Disclosure:		
Interest Paid	\$ 131,621	\$ 138,166
	=====	=====
Non-Cash Investing and Financing Activity -		
Equipment Acquired Under Capital Lease Obligations ..	\$ 64,409	\$ 209,648
	=====	=====

The accompanying notes are an integral part of the consolidated financial statements.

Edgar Filing: ROCKWELL MEDICAL TECHNOLOGIES INC - Form 10QSB

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. DESCRIPTION OF BUSINESS

We manufacture, sell and distribute hemodialysis concentrates and other ancillary medical products and supplies used in the treatment of patients with kidneys that do not function properly. We supply our products to medical service providers who treat patients with kidney disease. Our products are used to cleanse patients' blood and replace nutrients during the kidney dialysis process. We primarily sell our products in the United States.

We are regulated by the United States Food and Drug Administration (the "FDA") under the Federal Drug and Cosmetics Act, as well as by other Federal, state and local agencies. We have received 510(k) approval from the FDA to market hemodialysis solutions and powders. We also have 510(k) approval to sell our Dri-Sate(R) Dry Acid Concentrate product line and Dri-Sate(R) Dry Acid Mixing System.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

BASIS OF PRESENTATION

Our consolidated financial statements include our accounts and the accounts of our wholly owned subsidiary, Rockwell Transportation, Inc. All intercompany balances and transactions have been eliminated.

In the opinion of our management, all adjustments have been included which are necessary to make the financial statements not misleading. All of these adjustments that are material are of a normal and recurring nature. Our operating results for the three month period ended September 30, 2005 are not necessarily indicative of the results to be expected for the year ending December 31, 2005. You should read our unaudited interim financial statements together with the financial statements and related footnotes for the year ended December 31, 2004 included in our Annual Report on Form 10-KSB for the fiscal year ended December 31, 2004. Our Annual Report on Form 10-KSB for the fiscal year ended December 31, 2004 includes a description of our significant accounting policies.

REVENUE RECOGNITION

We recognize revenue at the time we transfer title to our products to our customers consistent with generally accepted accounting principles. Generally, we recognize revenue when our products are delivered to our customer's location consistent with our terms of sale. In most instances title for goods shipped internationally transfers to the buyer once it leaves our facility and therefore, we recognize revenue upon shipment to foreign customers.

We require certain customers, mostly international customers, to pay for product prior to the transfer of title to the customer. Deposits received from customers and payments in advance for orders are recorded as liabilities under Customer Deposits until such time as orders are filled and title transfers to the customer consistent with our terms of sale. At September 30, 2005, we had customer deposits of \$1,078,345.

EARNINGS PER SHARE

We computed our basic earnings per share using weighted average shares outstanding for each respective period. Diluted earnings per share also reflect the weighted average impact from the date of issuance of all potentially dilutive

Edgar Filing: ROCKWELL MEDICAL TECHNOLOGIES INC - Form 10QSB

securities, consisting of stock options and common share purchase warrants, unless inclusion would have had an antidilutive effect. Actual weighted average shares outstanding used in calculating basic and diluted earnings per share were:

	Three months ended September 30,		Nine months ended September 30,	
	2005	2004	2005	2004
Basic Weighted Average Shares Outstanding	8,680,952	8,551,814	8,633,866	8,543,874
Effect of Dilutive Securities	714,845	604,363	681,160	728,428
Diluted Weighted Average Shares Outstanding	9,395,797	9,156,177	9,315,026	9,272,302

Our reported and pro forma information for the three and nine months ended September 30:

	Three months ended September 30, 2005	Three months ended September 30, 2004	Nine months ended September 30, 2005
As reported net income (loss) available to common shareholders	\$156,177	\$ 65,277	\$350,849
Less: Stock based compensation expense determined under the fair market value method, net of tax	145,120	219,864	476,953
Pro forma net income (loss)	\$ 11,057	(\$154,587)	(\$126,104)
As reported basic earnings per share	\$ 0.02	\$ 0.01	\$ 0.04
As reported diluted earnings per share	\$ 0.02	\$ 0.01	\$ 0.04
Pro forma earnings (loss) per share and diluted earnings (loss) per share	\$ 0.00	(\$ 0.02)	(\$ 0.01)

3. LINE OF CREDIT

On March 29, 2005, we entered into a new line of credit with a financial institution. The loan agreement provides for revolving borrowings by us of up to \$2,750,000. We are permitted to borrow up to 80% of eligible accounts receivable and 40% of eligible inventory up to \$600,000. Borrowings under the loan agreement are secured by accounts receivable, inventory and certain other assets. The annual interest rate payable on revolving borrowings under the loan agreement is the lender's prime rate plus 75 basis points. The lender's commitment to make revolving borrowings under the loan agreement expires on March 31, 2006. As of September 30, 2005, we had borrowed \$1,400,000 under this

line of credit.

4. OTHER INCOME

We were the plaintiff in certain litigation that was settled in the first quarter of 2005. Since we have realized the full proceeds of the settlement, which totaled approximately \$241,000, we have recognized \$137,468 of other income from this settlement in the first quarter of 2005. A portion of the cash received was from the exercise of stock options by the defendant during the first quarter of 2005 which totaled \$103,750.

6

5. WARRANT EXCHANGE

On July 29, 2005, we filed with the Securities and Exchange Commission (the "SEC") a registration statement on Forms S-4 and SB-2 (the "Registration Statement") with respect to an offer to exchange new common share purchase warrants expiring January 26, 2006 with an exercise price of \$3.90 ("New Warrants") for each of the 3,625,000 currently outstanding common share purchase warrants expiring January 26, 2006 with an exercise price of \$4.50 ("Old Warrants"). The SEC declared the Registration Statement effective on October 20, 2005. Old Warrant holders must tender their Old Warrants by November 28, 2005 to participate in the exchange. Both Old and New Warrants expire January 26, 2006.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Some of the statements in this report are forward-looking statements. These forward-looking statements include statements relating to our performance in this Management's Discussion and Analysis of Financial Condition and Results of Operations. In addition, we may make forward-looking statements in future filings with the Securities and Exchange Commission and in written material, press releases and oral statements. Forward-looking statements include statements regarding the intent, belief or current expectations of us or our officers, including statements preceded by, followed by or including forward-looking terminology such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "projected," or similar expressions, with respect to various matters.

Our actual results might differ materially from those projected in the forward-looking statements depending on various important factors. These important factors include the cost of obtaining FDA approval to market our new iron supplemented dialysate product, the challenges associated with developing new products, the uncertainty of acceptance of our products by the hemodialysis community, competition in our market, and the other factors discussed under the caption "Risk Factors" in our Registration Statement on Form SB-2 (file no. 333-31991) effective January 26, 1998, our Registration Statement on Forms SB-2 and S-4 (file no. 333-127048), effective October 20, 2005, and elsewhere in our public filings and in this report, all of which constitute cautionary statements identifying important factors with respect to the forward-looking statements, including risks and uncertainties, that could cause actual results to differ materially from those in the forward-looking statements.

All forward-looking statements in this report are based on information available to us on the date of this report. We do not undertake to update any forward-looking statements that may be made by us or on our behalf in this report or otherwise.

Edgar Filing: ROCKWELL MEDICAL TECHNOLOGIES INC - Form 10QSB

OVERVIEW

We operate in a single business segment: the manufacture and distribution of hemodialysis concentrates, dialysis kits and ancillary products used in the dialysis process. Our business has gained market share each year and our sales have grown each year since our inception in 1996. In 2004, our revenue grew 20% to \$17.9 million and we earned \$211,000. We increased our sales by over 61% for the first nine months of 2005 compared to first nine months of last year. Our net earnings were \$351,000 in the first nine months of 2005 or \$.04 per share.

We believe that our core concentrate and supply business can continue to be profitable; however, the dialysis supply market is very competitive and we compete against companies that have substantially greater resources than we have. We expect to continue growing our business while executing our strategic plan to expand our product lines, expand our geographic reach and to develop our proprietary technology. We expanded our operations in the Southeastern United States by adding a third manufacturing facility in March of 2005. We have increased our plant capacity in order to position ourselves to take advantage of accelerated growth potential in our market. In the short run, we expect that these additional costs will reduce our gross profit margins until we successfully increase facility production volumes.

7

The dialysis industry is highly concentrated with several large clinic chains representing the majority of the industry. We expect that the consolidation of large and regional dialysis service providers will continue in the future. Our largest customer, DaVita, Inc., the second largest dialysis treatment provider in the United States, recently completed the acquisition of the dialysis clinic business of Gambro Healthcare U.S. in October, the third largest dialysis treatment provider in the United States. How this transaction may impact our market or our results is not clear at this time; however, we believe these events may prove beneficial in our business development efforts.

We are seeking to gain FDA approval for our iron supplemented dialysate product (which we also refer to as dialysate iron). We believe our iron supplemented dialysate product has the potential to compete in the iron maintenance therapy market. If we are successful in introducing our dialysate iron product, we believe it is possible that we may also increase our market share for the other products we sell. The cost to obtain regulatory approval for a drug in the United States is substantial and we expect that the development costs of our iron supplemented dialysate product will require us to raise additional funds or collaborate with a strategic partner. These substantial costs include those expected to be incurred in order to conduct required clinical trials and to obtain marketing approval which costs may offset some or all of any profits generated from sales of our existing products during the approval process, and we may incur losses. We expect the approval process to take between two and three years and there is no assurance we will be successful.

RESULTS OF OPERATIONS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2005

Our sales in the third quarter of 2005 were \$7,828,262 and increased by 75%, or \$3,354,000, over the third quarter of 2004. Sales of our dialysis concentrates represented 72% of our sales in the third quarter of 2005 and increased 45.7% over the third quarter of 2004. Sales of our kits and ancillary products increased by \$1.6 million largely as a result of an increase in dialysis kit sales primarily due to the purchase order described below.

Edgar Filing: ROCKWELL MEDICAL TECHNOLOGIES INC - Form 10QSB

We received a significant purchase order from a single distributor for dialysis products totaling \$6,500,000 late in the first quarter of 2005 and fulfilled approximately \$2.4 million in the third quarter, which is included in our sales results. We anticipate filling the remaining \$960,000 of this purchase order during the fourth quarter of 2005. We anticipate that similar purchase orders may recur in the future. However, it is possible that they may not recur in the future or repeat in each succeeding period.

Gross profit was \$959,988 in the third quarter of 2005, which represented an increase of 33.2%, or \$239,000, from the third quarter of 2004. Sequentially, third quarter 2005 gross profit increased \$150,000 over the second quarter of 2005, with gross profit margins improving by 1.9 percentage points from 10.4% in the second quarter of 2005 to 12.3% in the third quarter of 2005. Our margins had dropped earlier in 2005 due to a combination of temporary and recurring cost increases. We realized improvements in gross profit margins in the third quarter as temporary cost increases from our expansion efforts in the first half of 2005 did not recur in the third quarter.

Our overall gross profit margins in the third quarter of 2005 were 12.3% as compared to 16.1% in the third quarter of 2004. There were several factors, both recurring and non-recurring, contributing to the reduction in gross profit margins compared to the year earlier period including the expansion of our production operations, higher product delivery costs due to fuel increases and higher costs for equipment maintenance caused by increased production volumes.

We made an investment in the geographic expansion of our business in order to position the Company to take advantage of new business opportunities in our market. In March of 2005, we added a third manufacturing facility in the Southeastern United States that increased our costs of operation. We moved certain production, related to business in that region, to the new facility from our other facilities, which added flexibility at our other facilities to absorb additional volume growth. As a result, we added additional operating costs which have not been completely offset by higher production volumes. The current facility in the Southeast is being leased under a short term lease agreement that is set to expire on December 10, 2005. We may renew the lease on this facility or we may relocate to another facility if we do not renew our lease at our current facility. How a lease renewal or relocation of our facility may impact our operating costs is not clear at this time. We anticipate that having a facility in the Southeastern United States will enable us to realize improvements in

8

distribution efficiencies and will mitigate the negative impact from supplying the Southeastern United States from our other facilities.

Overall, our recurring operating costs have increased and have reduced our gross profit margins by over two percentage points compared to the third quarter of 2004. Cost increases included higher fuel costs for delivery, which we estimate to have decreased gross profit margins by 1.5 percentage points in the third quarter. Other increases in cost include additional production resources that will provide us with additional speed and flexibility in handling new business in the future.

Selling, general and administrative expense as a percent of sales in the third quarter of 2005 decreased to 9.7% of sales from 13.5% of sales in the third quarter of 2004 or an improvement of 3.8% of sales. Our selling, general and administrative expenses increased \$152,515, or 25.2%, compared to the third quarter of 2004. The majority of the cost increase was due to additional personnel resources and internal information technology infrastructure added to

Edgar Filing: ROCKWELL MEDICAL TECHNOLOGIES INC - Form 10QSB

handle increased transaction activity associated with our 61% sales increase in the first nine months of 2005. Our third quarter 2005 spending on the dialysate iron project of \$74,000 was an increase of \$35,000 over the third quarter of last year.

Operating income in the third quarter of 2005 was \$201,169, which was an improvement in profitability of 76%, or \$87,000, compared to the third quarter of 2004. Operating income to sales was 2.6% in both periods.

Net interest expense for the third quarter of 2005 was \$44,992 and decreased \$4,087 compared to the third quarter of last year largely as a result of lower average borrowings and lower effective interest rates under our new line of credit.

Net Income for the third quarter of 2005 was \$156,177, or 2.0% of sales, which was \$90,901, or 139%, higher than the third quarter of 2004. Basic earnings per share doubled to \$.02 per share compared to earnings per share of \$.01 in the third quarter of 2004. Similarly, diluted earnings per share were \$.02 in the third quarter of 2005 and double the \$.01 per share in the third quarter of 2004.

Our sales for the first nine months of 2005 were \$21,238,803 and were 61%, or \$8,074,163, higher than the first nine months of 2004. In the first three quarters of 2005, 73.5% of our sales consisted of dialysis concentrate sales, and sales of our concentrates increased by over 45.9% in the first nine months of 2005 compared to the first nine months of 2004. We have been successful at developing new business over the last year with our growth attributable to unit volume increases across the breadth of our product lines. Our growth has been attributable to both new dialysis centers purchasing products from our core concentrate product lines and to a substantial purchase order from a single distributor for which we recorded revenue of \$5.6 million in the first nine months of 2005. Sales of our ancillary products grew by \$3.1 million, primarily as a result of increases in sales of specialty kits from this distributor's purchase order.

We have continued to realize sales growth with national and regional dialysis chains throughout the eastern half of the United States over the last year. In February of 2005, we announced that we had signed multiple supply agreements with several dialysis chains and regional units of national chains in the Southeastern United States. The aggregate annual revenue from these dialysis chains is anticipated to be approximately \$2,500,000. We began to fulfill these supply agreements beginning in March of 2005, and we realized the full quarterly revenue impact during the second quarter of 2005. We also opened a third manufacturing facility in March 2005 to support the business under these supply agreements in addition to our existing portfolio of business in the Southeastern United States.

We achieved accelerated growth in the Southeastern United States through the sale of our liquid acid concentrate product lines over the last nine months. Overall, we experienced substantial unit growth in our liquid products with the aggregate gallons of liquid acid concentrate sold increasing by over 100% in the first nine months of 2005 over the same period last year. The majority of the liquid volume increase was in the Southeastern United States. We achieved a faster and more profitable operational start-up by gaining a critical mass of customers in a short time frame by penetrating the

Southeast region with liquid products, which was the primary catalyst behind the increased liquid demand. We intend to continue to attempt to convert our liquid

Edgar Filing: ROCKWELL MEDICAL TECHNOLOGIES INC - Form 10QSB

concentrate customers to our Dri-Sate Dry Acid Concentrate products.

Our overall gross profit for the first nine months of 2005 increased by \$342,000, or 16.3%, while our gross profit margins decreased by 4.4 percentage points to sales. There were both recurring and non-recurring factors that impacted gross profit margins, including the expansion of our production operations, transition costs as we moved order fulfillment operations between regions, higher product delivery costs due to fuel increases and higher costs for equipment maintenance caused by increased production volumes.

We made an investment in the geographic expansion of our business in order to position the Company to take advantage of new business opportunities in our market. In March of 2005, we added a third manufacturing facility in the Southeastern United States that increased our costs of operation. We moved certain production, related to business in that region, to the new plant from our other facilities, which added flexibility to our other facilities to absorb additional volume growth. As a result, we added additional operating costs which have not been completely offset by higher production volumes. The current facility in the Southeast is being leased under a short term lease agreement that is set to expire on December 10, 2005. We may release this facility or we may relocate to another facility if we do not renew our lease at our current facility. How a lease renewal or relocation of our facility may impact our operating costs is not clear at this time. We anticipate that having a facility in the Southeastern United States will enable us to realize improvements in distribution efficiencies and will mitigate the negative impact from supplying the Southeastern United States from our other facilities.

Our strategy was to expeditiously penetrate the Southeastern region of the U.S. and install a self-sustaining operation in the region in a short period of time. We added over \$5,000,000 in new annualized revenue over the last year in that market. We have added a facility but have incurred start-up costs for transition, above normal distribution expense to ensure continuity in product supply and additional operating costs for the new operation. We estimate that the transition costs including above normal operating costs were equivalent to approximately two gross profit margin percentage points in the first nine months of 2005. The remainder of the cost increases are the result of additional production personnel and resources. We anticipate improvement in our overall gross profit margins as we increase our respective plant volumes in the future.

Selling, general and administrative expense decreased as a percentage of sales by 3.4% to 9.9% for the first nine months of 2005 as compared to the first nine months of 2004. Overall, selling, general and administrative expense increased by \$335,253, or 19.1%. Approximately \$200,000 of the increase was for sales and administrative personnel to handle increased transaction activity. We also incurred approximately \$35,000 in higher operating expenses for computer infrastructure costs and over \$50,000 in other operating and selling expenses related to our substantial sales growth. In addition, we increased spending on development of our dialysate iron product by over \$55,000 from the first nine months of last year. We have recognized \$160,000 in costs related to dialysate iron product development in the first nine months of 2005.

Interest expense decreased by \$6,582 in the first nine months of 2005 compared to the prior period, primarily due to a lower effective interest rate under our new line of credit.

We were the plaintiff in certain litigation that was settled in the first quarter of 2005. We have recognized \$137,468 of other income from this settlement in 2005. A portion of the cash received was from the exercise of stock options by the defendant during the first quarter of 2005 which totaled \$103,750.

Net income in the first nine months of 2005 was \$350,848, an improvement

Edgar Filing: ROCKWELL MEDICAL TECHNOLOGIES INC - Form 10QSB

of 75%, or \$150,730, over the first nine months results in 2004. Basic earnings per share for the first nine months of 2005 aggregated \$.04, which was double the basic earnings per share for the first nine months of 2004 of \$.02. Similarly, diluted earnings per share also doubled to \$.04 per share in the first nine months of 2005 as compared to \$.02 for the first nine months of 2004.

10

LIQUIDITY AND CAPITAL RESOURCES

Our strategy is to expand our operations to serve dialysis providers throughout the United States. We anticipate that, as a result of our existing supply agreements, our customer relationships and our changing market dynamics, we have the opportunity to capture substantial market share. We expect that we will continue to realize substantial revenue growth and that we will require additional working capital and capital expenditures to fund this growth. In addition, over the next several years, we expect to make substantial investments in our dialysate iron product in order to gain FDA approval to market dialysate iron.

In the first nine months of 2005, we generated cash from our business operations and reinvested those funds into the development and expansion of our business. We realized substantial revenue growth of over 61% in the first nine months of 2005. Based on current and prospective developments that we anticipate in our business in the remainder of 2005 and in 2006, we will require additional working capital and capital expenditures to support our development plans. Our current credit line coupled with positive cash flow from operations is expected to provide the majority of the funding that we anticipate that we may need to support future growth of our core concentrate and dialysis supply business.

In addition to funding provided by operations, we intend to raise additional capital. We continue to engage in discussions with various potential financing sources including potential lenders, strategic partners and investors.

In addressing our need for additional working capital, we obtained a new line of credit with a financial institution, at the end of the first quarter of 2005, which expands our borrowing capacity. This credit line has a \$2.75 million credit limit. We are permitted to borrow up to 80% of our eligible accounts receivable and 40% of eligible inventory up to \$600,000. As of September 30, 2005, we had borrowed \$1,400,000 under this line of credit.

We are seeking FDA approval for our dialysate iron drug product. The development and approval of drugs can be expensive and take a long time. The development and approval costs may offset some or all of our earnings during the approval process. We estimate the cash required to fund approval of our new iron supplemented dialysate product will total between \$5,000,000 - \$7,000,000 and be expended over the next several years. We may raise these funds ourselves or if we do not raise the capital to fund this project ourselves, we may decide to seek a partner with greater technical and financial resources to facilitate approval of this product.

On July 29, 2005, we filed with the Securities and Exchange Commission (the "SEC") a registration statement on Forms S-4 and SB-2 (the "Registration Statement") with respect to an offer to exchange new common share purchase warrants expiring January 26, 2006 with an exercise price of \$3.90 ("New Warrants") for each of the 3,625,000 currently outstanding common share purchase warrants expiring January 26, 2006 with an exercise price of \$4.50 ("Old Warrants"). The SEC declared the registration statement effective on October 20, 2005. Old Warrant holders must tender their Old Warrants by November 28, 2005 to participate in the exchange. Both Old and New warrants expire January 26, 2006.

Edgar Filing: ROCKWELL MEDICAL TECHNOLOGIES INC - Form 10QSB

We would not receive any proceeds from the completion of the exchange offer, although we would receive proceeds upon the exercise of the New Warrants. The net proceeds to the Company from the sale of the 3,625,000 common shares underlying the New Warrants would aggregate in excess of \$13,000,000. We intend to use the net proceeds of this offering for general working capital and may use the proceeds: to add additional manufacturing facilities, for research and product development and for clinical trials related to our efforts to obtain FDA approval of our iron dialysate product and the financing of marketing and sales activities.

If we are not successful in raising additional funds through exercise of warrants we may pursue other financing options. We plan to raise the capital required to expand our operations and fund our new product development strategy through a combination of cash flow from operations, debt or equity financing arrangements and/or licensing arrangements; however, we may not be successful. If we are not successful in raising additional funds, we may be required to alter our growth strategy, defer spending on business development, curtail production expansion plans or take other measures to conserve our cash resources.

11

In addition, the dialysis provider market that we serve is becoming increasingly concentrated. As a result, our business is predominantly with national and regional dialysis chains. If we were to lose a significant portion of our business with major national and regional dialysis chains, it could have a substantial negative impact on our cash flow and operating results. If we were to lose a substantial portion of our business, it may have a detrimental impact on our ability to continue our operations in their current form or to continue to execute our business strategy. If we lost a substantial portion of our business, we would be required to take actions to conserve our cash resources and to mitigate the impact of any such losses on our business operations.

ITEM 3. CONTROLS AND PROCEDURES

We carried out an evaluation under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures as of September 30, 2005. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective as of September 30, 2005 in ensuring that information required to be disclosed by us under the Exchange Act is recorded, processed, summarized and reported within the time periods specified under the Exchange Act rules and forms. There was no change in our internal control over financial reporting identified in connection with such evaluation that occurred during our fiscal quarter ended September 30, 2005 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Disclosure controls and procedures are our controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.

PART II - OTHER INFORMATION

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

During the third quarter of 2005, we issued 10,832 common shares upon exercise of warrants which were issued to investors in a private placement. The offer and sale of the above common shares upon exercise of the warrants were exempt from the registration requirements of the Act under Section 4(2) of the Act. We realized proceeds of \$8,560, or \$.79 per share on average. Warrant holders exercising these private placement warrants received a certificate with a restrictive legend representing the shares purchased.

ITEM 6. EXHIBITS

- 4.1 Warrant Agreement between Rockwell Medical Technologies, Inc. and American Stock Transfer & Trust Company, as Warrant Agent, incorporated by reference to Exhibit 4.1 on Form 8-K filed on October 20, 2005.
- 10.1 Second Amendment of Industrial Lease Agreement between Rockwell Medical Technologies, Inc. and DCT DFW, LP dated August 17, 2005, incorporated by reference to Exhibit 99.1 on Form 8-K filed on August 19, 2005.
- 31.1 Certifications of Chief Executive Officer Pursuant to Rule 13a-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 31.2 Certifications of the Chief Financial Officer Pursuant to Rule 13a-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 32.1 Certifications of the Chief Executive Officer and Chief Financial Officer, Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ROCKWELL MEDICAL TECHNOLOGIES, INC.
(Registrant)

Date: November 11, 2005

/s/ ROBERT L. CHIOINI

Robert L. Chioini
President, Chief Executive
Officer and Director (Principal
Executive Officer)

Date: November 11, 2005

/s/ THOMAS E. KLEMA

Thomas E. Klema
Vice President of Finance, Chief
Financial Officer, Treasurer and
Secretary (Principal Financial
Officer and Principal Accounting

Officer)

14

10-QSB EXHIBIT INDEX

EXHIBIT NO.	DESCRIPTION
EX-31.1	Certification of Chief Executive Officer Pursuant to Rule 13a-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
EX-31.2	Certification of the Chief Financial Officer Pursuant to Rule 13a-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
EX-32.1	Certifications of the Chief Executive Officer and Chief Financial Officer, Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

15